Medicinal plant-based drug delivery system for inflammatory bowel disease

Front Pharmacol. 2023 Mar 23:14:1158945. doi: 10.3389/fphar.2023.1158945. eCollection 2023.

Abstract

Inflammatory bowel disease (IBD) is a chronic recurrent intestinal disease. The incidence rate of IBD is increasing year by year, which seriously endangers human health worldwide. More and more studies have shown that medicinal plants or their main phytochemicals have great potential in the treatment of intestinal diseases. However, the disadvantages of low oral absorption rate, low biological distribution and low systemic bioavailability limit their clinical application to a certain extent. In recent years, the application of nanotechnology has made it possible to treat IBD. Nanoparticles (NPs) drug delivery system has attracted special attention in the treatment of IBD due to its small size, low immunogenicity, surface modification diversity, targeting and other advantages. Synthetic nanoparticles and extracellular vehicles (EVs) can deliver drug components to colon, and play a role in anti-inflammation, regulation of oxidative stress, improvement of intestinal flora, etc. In addition, some medicinal plants can secrete EVs by themselves, and carry biological molecules with therapeutic effects to act on the intestine. Some clinical trials to evaluate the safety, tolerance, toxicity and effectiveness of EVs-loaded drugs in IBD are also progressing steadily. This review introduces that synthetic nanoparticles and medicinal plants derived EVs can play an important role in the treatment of IBD by carrying the effective active phytochemicals of medicinal plants, and discuss the limitations of current research and future research needs, providing a scientific and reliable basis and perspective for further clinical application and promotion.

Keywords: drug delivery; extracellular vesicles; inflammatory bowel disease; medicinal plant; nanomedicine; plant exosome-like nanovesicles; synthetic nanoparticles; traditional Chinese medicine.

Publication types

  • Review

Grants and funding

This study was financially supported by the Research on the diagnosis and treatment model and intelligent assistant model of diabetes mellitus based on “State target differentiation and treatment” funded by Beijing municipal natural science foundation (No. L222135), Scientific and technological innovation project of China Academy of Chinese Medical Sciences (No. CI 2021B003), Research on effective prescription and drug discovery and curative effect evaluation based on real-world diagnosis and treatment data funded by the Chinese Academy of Chinese Medical Sciences (No. 2022029), China Postdoctoral Science Foundation (No. 2022M721536), National Natural Science Foundation of China (NSFC) (Nos. 82030125, 82105023).